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Abstract 
Cancer is a common cause of death in the United States and locally in the state of Arkansas. 
Modifiable factors such as tobacco use, physical activity, and diet lead to reduced incidence of 
colon cancer diagnosis. Fruits and vegetables contain phytochemicals that confer health 
promoting properties. Specifically, peanuts contain phytochemicals known as resveratrol, 
arachidin-1, and arachidin-3 that have been linked to anticancer activities. However, a few 
research studies have been done on arachidin-1 and arachidin-3 that could further develop 
understanding of their health promoting properties or nutraceutical applications. The objectives 
of this study were to (1) determine the most effective concentration of arachidin-1 and arachidin-
3 for inhibiting cell proliferation and (2) to assess the bioavailability of these compounds. 
Concentrations of 0, 5, 10, and 20 µM arachidin-1 and arachidin-3 were applied and cell viability 
was measured at 0, 24, and 48 hours. Significant reduction of cell proliferation occurred with 
treatments of 10 and 20 µM arachidin-1 and 10 and 20 µM arachidin-3 in comparison with the 
control. Due to the limit of HPLC detection, no transport values were determined when 
arachidin-1 and arachidin-3 were applied in 50 and 100 µM concentrations. The findings suggest 
that arachidin-1 and arachidin-3 inhibit cell proliferation in human colon cancer cells. Further 
research is needed to understand the bioavailability of arachidin-1 and arachidin-3.  
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Introduction 
Cancer is one of the leading causes of mortality in the state of Arkansas and around the 
United States. Specifically, an incidence rate of 50.1% per 100,000 for males and 37% per 
100,000 for females exists for colon cancer in the state of Arkansas (American Cancer Society, 
2017). The mortality rate for colon cancer in Arkansas is approximately 18.2% per 100,000 
people, which ranks third highest compared with other states in the United States (National 
Cancer Institute, 2015).  
Genetic and lifestyle factors are potentially influential in the development of colon cancer 
(Burt et al., 2010). Prevention is important in reducing incidence and mortality rates associated 
with colon cancer (American Cancer Society, 2016). Amin et al. (2009) reported an inverse 
relationship between a diet rich in fruits and vegetables and diagnosis with colon cancer. This 
relationship can be attributed to the phytochemicals found in fruits and vegetables (Amin et al., 
2009). The peanut plant (Arachis hypogaea L.) is a source of phytochemicals known as 
stilbenoids, which confer cancer preventative properties following extraction from the root or 
kernel of the peanut plant. Arachidin-1, arachidin-3, and resveratrol are stilbenoids derived from 
the peanut plant (Huang et al., 2010). While a significant amount of research has been conducted 
involving resveratrol, there is limited information available about the health-promoting 
properties of arachidin-1 and arachidin-3 (Chang et al., 2006).  
Understanding the bioavailability of phytochemicals is essential for determining their 
biological and health effects in humans. Therefore, the objectives of the present study were to: 1) 
determine the effective concentrations of arachidin-1 and arachidin-3 for inhibiting colon cancer 
cell growth, and 2) assess the intestinal transport of arachidin-1 and arachidin-3 to determine 
which compound is more bioavailable.  
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Literature Review 
Colorectal Cancer  
Cancer remains the second leading cause of death in the United States with a mortality 
rate of 22.9% (Heron, 2015). Mortality rates related to cancer vary among people of different 
age, sex, and racial backgrounds (Heron, 2015). A study conducted by Moghaddam et al. (2007) 
reported that cancer of the colon and rectum contributes to a major portion of the morbidity and 
mortality occurring globally. Colon and rectum cancer is projected as the third leading type of 
cancer for estimated new cases and estimated deaths in 2017 (Figure 1, American Cancer 
Society, 2017).  
Figure 1. 2017 Estimation of Leading Cancer Sites. (American Cancer Society, 2017) 
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Several factors can influence the development of colorectal cancer. In fact, 30% of 
colorectal cancer cases stem from mutated genes predisposing individuals for development of the 
disease. These mutations are diagnosed through genetic testing. Genetic factors may be 
especially influential in the development of colon cancer if the individual has Lynch syndrome, 
familial adenomatous polyposis, or several other genetic conditions (Burt et al., 2010). 
Additional factors affecting colorectal cancer incidence rates include Type II diabetes and a 
family history of colon cancer (American Cancer Society, 2016).  
About 70% of colorectal cancer cases are influenced by major lifestyle factors such as 
overweight/obesity, physical activity, alcohol consumption, tobacco use, and diet (American 
Cancer Society, 2016; Burt et al., 2010). These factors can be controlled by the lifestyle choices 
that individuals make (American Cancer Society, 2016). Precautionary measures such as regular 
health screenings in addition to consumption of a healthy diet for prevention of obesity can 
reduce colorectal incidence rates (American Cancer Society, 2016). Overweight or obesity 
resulting from lack of balance between nutritional intake and physical activity leading to excess 
weight increases the risk for colorectal cancer. An individual with obesity possesses a risk of 
20% greater for developing colorectal cancer than individuals of normal weight (Moghaddam et 
al., 2007).  
Epidemiological studies indicate that diet has implications on the incidence of colorectal 
cancer (Birt and Philips, 2014; Chan and Giovannucci, 2010; Chen et al., 2015; Kim and Milner, 
2007). Diets characterized by large quantities of red meat, alcohol, simple sugars and refined 
grains are associated with obesity and higher incidence of colorectal cancer (Chen et al., 2015). 
Conversely, a diet consisting of vegetables, fiber, legumes, whole grains, poultry, fish, and a low 
amount of dietary fat is associated with lower incidence of colorectal cancer (Chan and 
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Giovannucci, 2010). Phytochemicals found in fruits and vegetables hold potential for prevention 
of cancer due to antioxidant activity (Amin et al., 2009). 
 
Phytochemicals in the Peanut Plant  
 Chemical Structure of Resveratrol, Arachidin-1, and Arachidin-3  
Phytochemicals such as resveratrol (trans-3,5,4’- trihydroxystilbene), arachidin-1 [trans-4-(3-
methyl-1-butenyl)-3,5,3’,4’-tetrahydroxysilbene)], and arachidin-3 [trans-4-(3-methyl-1-butenyl)-3,5,4’-
trihydroxystilbene)] are stilbenoids derived from the peanut plant. Each of these phytochemicals 
have similar chemical structures.  Arachidin-1 and arachidin-3 are the prenylated analogs of 
resveratrol. Figure 2 demonstrates the structural similarities of these compounds. 
 
 
 
 
 
 
 
Figure 2. Chemical Structures of Resveratrol, Arachidin-1, and Arachidin-3. (Ball et al., 2015.)   
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 Concentrations of Resveratrol, Arachidin-1, and Arachidin-3 in the Peanut 
Resveratrol is found in various parts of the peanut plant in addition to being available in 
processed foods (Chang et al., 2006). Resveratrol in peanuts prepared by boiling contains 5.1 µg 
resveratrol per gram of boiled peanut while peanut butter contains 0.3 µg resveratrol per gram. 
No studies have detected arachidin-1 and arachidin-3 in peanuts. However, arachidin-1 and 
arachidin-3 are obtained for research purposes via extraction and purification from seeds and 
roots of the peanut plant, and range from 0.4 to 5.7 nmol/g dry weight (Condori et al., 2010).  
 
Health Effects of Phytochemicals in the Peanut  
 Anti-Inflammatory Properties  
Antioxidant activity of resveratrol has been widely investigated. This stilbenoid has been 
linked to anti-inflammatory effects through in-vitro cell study (Chang et al., 2006; Djoko et al., 
2007; Huang et al., 2010). In a particular study, 15 µM arachidin-1, 15 µM arachidin-3, and 15 
µM resveratrol were applied to RAW 264.7 mouse macrophage cells to cause inhibition of LPS 
(lipopolysaccharide)-induced responses (Chang et al., 2006). Macrophage cells are essential for 
inflammation, infection, and immune response. LPS results in activation of macrophage cells to 
secrete inflammatory responses such as prostaglandins (PGs) and nitric oxide (NO). The 
production of these mediators is associated with inflammation within the cell. Application of all 
three stilbenoids to RAW 264.7 macrophage cells resulted in reduced inflammation activity. Of 
the three, resveratrol yielded the greatest anti-inflammatory effect. Arachidin-1 yielded greater 
anti-inflammatory effects than arachidin-3 (Chang et al., 2006).  
Nuclear factor kappa B (NF-𝜅B) is a heterodimeric protein consisting of different 
combinations of transcription factors. NF- 𝜅B plays a major role in regulating transcription of 
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genes for cytokine production and cell survival. Activation of NF- 𝜅B is associated with 
inflammation, cancer, and autoimmune diseases (Badr et al., 2009). 
In a study conducted by Djoko et al. (2007), stilbenoids of similar structure including 
arachidin-1, piceatannol, and resveratrol were investigated for the reduction of inflammatory 
effects in RAW 264.7 mouse macrophage cells. The inhibition of LPS-induced NO and PGE2 
production was evaluated to determine their role in immune functions. The NF-𝜅B activity 
leading to inflammatory gene expression was also monitored (Djoko et al., 2007). The treatment 
of stilbenoids including resveratrol, piceatannol, and arachidin-1 correlates with reduced NF- 𝜅B 
activity in RAW 264.7 macrophage cells. All three compounds inhibited productions of PGE2 
and NO in a dose-dependent manner. Arachidin-1 and resveratrol were applied in concentrations 
of 3.75, 7.50, 15.0, and 30.0 µM while piceatannol was applied at 1.88, 3.75, 7.5, and 15 µM 
concentrations. Application of arachidin-1, resveratrol, and piceatannol resulted in reduced 
inflammation responses. This study indicates that these derivatives have potential to contribute to 
nutraceutical applications by providing anti-inflammatory effects (Djoko et al., 2007). More 
research is needed to further determine the anti-inflammatory effects of prenylated stilbenoids 
(arachidin-1 and arachidin-3) since these derivatives have been less researched. 
Anti-Cancer Properties of Phytochemicals  
 Excluding resveratrol, anticancer properties of stilbenoids have been minimally 
investigated. However, in the studies that have been done, resveratrol, arachidin-1, and 
arachidin-3 have also been linked to anti-cancer properties (Huang et al., 2010; Amin et al., 
2009; Ko et al., 2013; Ball et al., 2015). Resveratrol and arachidin-1 induce anticancer activity 
by causing programmed cell-death or apoptosis in human leukemia HL-60 cells (Huang et al., 
2010). Arachidin-1 was more effective than resveratrol for inducing programmed cell-death 
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(PCD) when both compounds were applied in concentrations of 0-20 µM. Optimal 
concentrations for achieving cell death were 4.2 and 17.6 µM, respectively, for arachidin-1 and 
resveratrol. Programmed cell-death is essential for maintaining equilibrium in cell division 
patterns. This occurs because caspase-independent pathways are activated in the process of PCD 
and these pathways lead to apoptosis when cells contain mutations in apoptotic genes (Huang et 
al., 2010). Apoptosis is important in eliminating mutated cells that can lead to the development 
of cancer (Badr et al., 2009). Cell exposure to arachidin-1 caused PCD to occur more efficiently 
than resveratrol due to activation of both caspase-dependent and caspase-independent pathways 
(Huang et al., 2010).  
The results reported in Athar et al. (2009) support that resveratrol suppresses cancer cell 
growth by influencing cell cycle kinase activity and accumulation of p53 in cells. Cell cycle 
kinases are involved in the development of colorectal cancer and leukemia by phosphorylating 
receptors on the cell to affect tumorigenesis. Resveratrol stops transition between cell cycle 
phases so that cells with mutated DNA either cannot double their DNA or divide (Athar et al., 
2009). Resveratrol also increases p53 levels and decreases Bcl-2 levels. P53 is a transcription 
factor that functions as a tumor suppressor gene and monitors for mutations. Bcl-2 is an anti-
apoptosis protein that is expressed less frequently with increased p53 levels present in a cell. As 
a result, high levels of p53 and low levels of Bcl-2 resulting from exposure of cells to resveratrol 
can lead to apoptosis of cancer cells (Athar et al., 2009). Since arachidin-1 and other stilbenoids 
are similar in structure to resveratrol, these stilbenoids have the potential to confer anticancer 
properties. It is necessary to further investigate the specific roles of arachidin-1 and arachidin-3 
in anticancer effects. 
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Bioavailability of Phytochemicals in Peanut Plant 
Bioavailability refers to the rate at which a nutrient is sent to the bloodstream for use in 
the body (Parada and Aguilera, 2007). Chukwumah et al. (2011) evaluated the transport and 
absorption of trans-resveratrol using a Caco-2 cell monolayer. The preparation of the peanut 
derivative impacts the rate of transport, or bioavailability. A study examining bioavailability of 
trans-resveratrol used different preparation methods including boiling and roasting the peanuts. 
Roasted peanuts yielded better transport ability for trans-resveratrol than boiled peanuts 
(Chukwumah et al., 2011).  
Bioavailability studies on arachidin-1 and arachidin-3 are not available. However, a 
strong understanding of bioavailability for arachidin-1 and arachidin-3 is necessary so that 
knowledge of biological activity by the compounds are available. 
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Materials and Methods 
Materials   
Arachidin-1 and arachidin-3 were generously donated by Dr. Medina-Bolivar in their 
pure form (Arkansas State University, Jonesboro, AR). All reagents and media components were 
purchased from ThermoFisher (Waltham, MA).   
 
Methods 
HPLC Analysis 
To measure arachidin-1 and arachidin-3, a System Gold high performance liquid 
chromatograph (Beckman-Coulter, Fullerton, CA, USA) with autosampler (model 508), dual 
pump (model 126), photodiode array detector (model 168) with Beckman-Coulter System 32 
Karat software (version 8, 2006) was used. Arachidin-1 and arachidin-3 were separated using the 
method proposed by Abbott et al. (2010) to ensure the compounds being used for the study were 
pure. Separation of the phytochemicals occurred with the Phenomenex (Torrance, CA) Aqua 5 
µM C18 (250 x 4.6 mm) column containing a binary gradient of 2% formic acid [mobile phase 
A] and 99:1 (v/v) acetonitrile/mobile phase A [mobile phase B]. The gradient began with 10% B 
and increased uniformly to 18% for approximately 8 minutes. The gradient was then held at 18% 
B for 2 minutes before increasing linearly to 25% B over the course of 5 minutes, and increasing 
to 35% B for 3 minutes. Then the gradient remained isocratic or constant and uniform in the 
mobile phase for 20 minutes at 35%. B increased uniformly to 60% over the course of 59 
minutes before returning to the initial binary gradient of 10%. The peaks of arachidin-1 and 
arachidin-3 were monitored at 340 nm. 
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Cell Culture 
Caco-2 cells, a human epithelial colorectal adenocarcinoma cell line, purchased from 
American Type Culture collection (ATCC, Rockville, MD) were incubated at 37°C in an 
atmosphere containing 5% 𝐶𝑂2. Cells were cultivated in Dulbecco’s Modified Eagle’s Medium 
(DMEM) with 10% fetal bovine serum (FBS), 1 % nonessential amino acids solution, and 1% 
antibiotic-antimycotic. Cell cultures were maintained under sterile conditions and incubated at 
37°C, 70% humidity, and 5% CO2 in the incubator (VWR® symphony™, VWR® International 
LLC, Radnor, PA).  
 
Cell Viability Assay 
Caco-2 cells, passage number 36-42, were used for the viability assay. For a standard 
curve, cells attached to the chambers of a 96-well microplate (Corning Inc., Tewksbury, MA) for 
24 hours after being seeded in a range from 0 to 3.2x103 cells with 100 µL working media 
(WMEM). For the experiment, cells (2 x 103) were seeded in wells of a 96 well plate for 24 
hours. Three separate plates were prepared for each experiment. A total of five experiments were 
performed over the course of this study. At the end of the 24 hour period, the media was 
aspirated and then cells were treated with 100 µL of 0, 5, 10, or 20 µM concentration of 
arachidin-1 or arachidin-3. These concentrations were chosen based off of results from previous 
studies evaluating cell viability. Dried arachidin-1 or arachidin-3 was suspended in DMEM in 
the quantity deemed calculated when the density was converted to moles. The compounds were 
then suspended in media to make a 100 µM stock solution and then dilutions with media were 
made accordingly. Each treatment was applied in quadruplicate. The control was treated with 
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100 µL of 0.1% DMSO. Measurements were obtained at 0 (T0), 24 (T24), and 48 (T48) hours 
following treatment in order to determine cell viability. When the absorbance was read at T0-
T48, 20 µL of cell titer reagent (CellTiter96® Aqueous One Solution Proliferation Assay, 
Promega Co., Madison, WI) was added to each well. Using a plate reader (Synergy HT Multi-
Mode Microplate Reader, BioTek Instruments, Inc. Winooski, VT) the absorbance of the cells 
were measured at 490nm. This absorbance was converted to the number of viable cells using an 
equation from the standard curve. Based on the number of viable cells present at T0, a 
proliferation percentage was calculated for T24 and T48.  
 
Intestinal Transport Assay 
Caco-2 cells were seeded at a density of 1 x 105/cm2 cells on polycarbonate membrane 
inserts (12 mm diameter, pore size 0.4 µM) fitted in bicameral chambers (Corning Inc., 
Tewksbury, MA). Cell monolayer integrity was confirmed by determining the transepithelial 
electrical resistance (TEER) values using the Millicell ERS-2 Voltohmmeter (EMD Millipore, 
Billerica, MA). After seeding, media was aspirated from both the apical and basal chambers. 1 
mL of PBS was added to the basal chamber and 0.5 mL of 50 and 100 µM arachidin-1 or 
arachidin-3 was added to the apical chamber.  
For time 0h, transport media containing arachidin-1 (or arachidin-3) was loaded and 0.5 
mL of PBS were collected immediately in a vial. Each vial is preserved with 25 µL 
trifluoroacetic acid (TFA) and 25 µL 70% ethanol. At this point, 0.5 mL of PBS was replaced in 
the basal chamber. The plate was incubated at 37°C for 30 minutes. For time 0.5h and time 1h, 
steps performed for time 0 were repeated. The plate was incubated for 1 hour following time 1. 
At the end of 2 hours, media from the apical was collected in a vial and rinsed with 0.5 mL of 
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PBS three times. PBS was removed from the basal chamber, collected in a vial, and rinsed with 1 
mL of PBS. Each vial was preserved with 25 µL TFA and 25 µL 70% ethanol. All aliquots were 
frozen at -20°C until analysis via HPLC. Apparent permeability coefficients (Papp) was calculated 
using the following equation:                                        
                                                                                                             
Where dQ/dt is the rate of permeation across the cell, A is the area of the cell monolayer, and C0 
is the initial concentration of the apical chamber. 
 
Statistical Analysis  
All statistical analyses were carried out by JMP software (version 13; SAS Institute Inc., 
Cary, NC) using a one-way analysis of variance test (ANOVA). ANOVA results were compared 
with the student’s t test. Data was represented as means ± standard error of mean (SEM). 
Statistically significance was accepted at P<0.05. 
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Results 
Identification of Arachidin-1 and Arachidin-3  
Arachidin-1 and arachidin-3 used for this experiment were identified  as pure compounds 
at 304 nm. The results are shown in Figure 3.  
  
Figure 3. High Performance Liquid Chromatogram of arachidin-1 and arachidin-3 at 340 nm.  
 
Cell Viability after Arachidin-1 and Arachidin-3 Treatment  
The data presented in Figures 4 and 5 shows that arachidin-1 and arachidin-3 treatments 
(10 µM and 20 µM) reduced cell viability compared to control. 
At the 48 hour time point, 10, and 20 µM concentrations of arachidin-1 resulted in a 
significant reduction of cell viability (%) compared to the control (P<0.05) (Figure 4). There was 
no significant difference of cell viability between treatments and control at time point 24 hours.  
The cell viability was significantly reduced in treatments of 10 and 20 µM arachidin-3 
compared to 5 µM arachidin-3 and the control at time point 48 hours (P<0.05) (Figure 5).  
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Figure 4. Effect of arachidin-1 on the survival of Caco-2 cells. Values with different letters at 
the same incubation time are significantly different (P<0.05).  
 
 
      
Figure 5. Effect of arachidin-3 on the survival of Caco-2 cells. Values with different letters at 
the same incubation time are significantly different (P<0.05). 
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At time point 48 hours, 10 and 20 µM concentrations of arachidin-1 showed the lowest 
cell viability in comparison with cell viability measured after treatments of 10, or 20 µM 
arachidin-3 or control (P<0.05). 
 
Figure 6. Summarized effects of arachidin-1 and arachidin-3 on the survival of Caco-2 cells. 
Values with different letters at the same incubation time are significantly different (P<0.05). 
 
 
Intestinal Transport Assay of Arachidin-1 and Arachidin-3 Treatment  
Arachidin-1 was not detected in samples from both apical and basal chambers treated 
with 50 µM or 100 µM at time point 2 hr (Figure 7). At time point 2 hr, a trace amount of 
arachidin-3 was detected in apical sample treated with 100 µM (Figure 8). Apparent permeability 
coefficient (Papp) values of arachidin-1 and archidin-3 were not determined. 
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Figure 7. HPLC Chromatogram of (A) arachidin-1 standard, (B) apical sample treated with 100 
µM of arachidin-1 and (C) basal sample treated with 100 µM of arachidin-1 at time point 2 hr.    
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Figure 8. HPLC Chromatogram of (A) arachidin-3 standard, (B) apical sample treated with 100 
µM of arachidin-3 and (C) basal sample treated with 100 µM of arachidin-3 at time point 2 hr.    
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Discussion 
The peanut root contains phytochemicals that confer anticancer and anti-inflammatory 
effects to the body for a nutraceutical approach. Arachidin-1 and arachidin-3, derivatives from 
the peanut plant, have been involved in limited research relating to their health effects in the 
body for cancer prevention. Therefore, the anti-colon cancer activity and bioavailability of 
arachidin-1 and archidin-3 have been investigated in this study.  
In order to understand the anticancer properties linked with arachidin-1 and arachidin-3, 
it is important to evaluate the effect of these compounds on colon cancer cell proliferation. In the 
present study, both arachidin-1 and arachidin-3 treatments (10 and 20 µM) resulted in reduced 
cell proliferation rates compared with the control (P<0.05). The most significant reduction of cell 
proliferation occurred  at time point 48 hours when arachidin-1 was applied at concentrations of 
10 and 20 µM in comparison with the control or 5, 10, and 20 µM arachidin-3 treatments 
(P<0.05).  
The limited studies have investigated the anticancer properties of arachidin-1 and 
arachidin-3 in different cell lines with different concentrations of stilbenoids (Huang et al., 2010; 
Ko et al., 2013; Ball et al., 2015). Cell viability results from a study on the effect of 0 to 20 µM 
concentrations of arachidin-1, arachidin-3, and resveratrol on human leukemia cell (HL-60) 
proliferation reported that arachidin-1 resulted in reduced cell viability (Huang et al., 2010). 
Another study investigated the effects of metformin and arachidin-1 upon dose-dependent 
application to A549 and H1975 human lung cancer cell lines. Metformin is an anti-diabetic drug 
that is associated with anticancer properties. Treatments of 0.5, 1, 5, and 10 µM arachidin-1 with 
25 µM metformin over the course of a 4-day incubation period resulted in reduced cell viability. 
(Ko et al., 2013).  
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 10 and 20 µM concentrations of arachidin-1, resveratrol, piceatannol, and arachidin-3 
were applied to rotavirus infected HT29.F8 cells from the human adenocarcinoma line of the 
intestine. These concentrations of stilbenoids did not result in a substantial decrease in cell 
viability. However, application of arachidin-1 or arachidin-3 resulted in reduced viral replication 
and can be attributed to antioxidant activity of these compounds (Ball et al., 2015). Additional 
research must be conducted to understand the effects of stilbenoids from the peanut plant on cell 
viability. 
Previous studies regarding the transport abilities of arachidin-1 and arachidin-3 have not 
been conducted. Due to the limit of detection in the HPLC system, the apparent transport of 
arachidin-1 and arachidin-3 were not calculated. Additional research must be conducted with 
higher concentrations of arachidin-1 and arachidin-3 in order to evaluate bioavailability.  
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Conclusions 
The results of this study indicate that concentrations greater than 10 µM arachidin-1 and 
arachidin-3 did reduce cell viability in human colon cancer cells in comparison with the control. 
Arachidin-1 was more effective for inhibiting cell proliferation than arachidin-3. No apparent 
intestinal transport occurred, so it is likely that concentrations of arachidin-1 and arachidin-3 
greater than 100 µM are needed to determine bioavailability. Additional research is needed to 
establish the chemopreventative or nutraceutical applications of arachidin-1 and arachidin-3.  
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